Morphic Therapeutic (MORF) stock price, revenue, and financials
Morphic Therapeutic market cap is $939.7 m, and annual revenue was $3.36 m in FY 2019
$30.1
$939.7 M
MORF Mkt cap, 15-Jan-2021$7.7 M
Morphic Therapeutic Revenue Q2, 2020Morphic Therapeutic Net income (Q2, 2020)-15.9 M
Morphic Therapeutic EBIT (Q2, 2020)-16.4 M
Morphic Therapeutic Cash, 30-Jun-2020133.1 M
Morphic Therapeutic Income Statement
Annual
Quarterly
| USD | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|
Revenue | 5.6m | 5.6m | 7.7m | |
R&D expense | 13.9m | 12.6m | 19.0m | 19.9m |
General and administrative expense | 2.1m | 2.9m | 4.4m | 4.2m |
Operating expense total | 16.0m | 15.5m | 23.4m | 24.1m |
EBIT | (10.4m) | (9.9m) | (17.8m) | (16.4m) |
EBIT margin, % | (187%) | (318%) | (213%) | |
Interest expense | 1.1m | 886.0k | 407.0k | |
Interest income | 1.4m | |||
Pre tax profit | (9.3m) | (8.6m) | (16.9m) | (16.0m) |
Income tax expense | 135.0k | (304.0k) | (157.0k) | (155.0k) |
Net Income | (9.4m) | (8.9m) | (16.7m) | (15.9m) |
Morphic Therapeutic Balance Sheet
Annual
| USD | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|
Cash | 20.8m | 185.9m | 101.6m |
Accounts Receivable | 3.5m | ||
Prepaid Expenses | 479.0k | 1.2m | 3.1m |
Current Assets | 21.2m | 187.1m | 243.6m |
PP&E | 1.7m | 1.8m | 3.4m |
Total Assets | 23.2m | 189.3m | 247.4m |
Accounts Payable | 883.0k | 1.7m | 5.2m |
Short-term debt | 315.0k | ||
Current Liabilities | 2.5m | 34.9m | 35.4m |
Long-term debt | 315.0k | ||
Total Debt | 630.0k | ||
Total Liabilities | 3.2m | 102.0m | 106.5m |
Common Stock | 3.0k | ||
Preferred Stock | 49.7m | 139.8m | |
Additional Paid-in Capital | 661.0k | 1.6m | 238.4m |
Retained Earnings | (97.5m) | ||
Total Equity | 20.0m | 87.3m | 140.9m |
Financial Leverage | 1.2 x | 2.2 x | 1.8 x |
Quarterly
| USD | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|
Cash | 44.2m | 159.8m | 107.0m | 133.1m |
Accounts Receivable | 945.0k | 2.4m | 3.7m | 3.5m |
Prepaid Expenses | 1.4m | 2.9m | 2.9m | 2.5m |
Current Assets | 172.8m | 257.0m | 225.6m | 208.6m |
PP&E | 2.5m | 2.7m | 3.2m | 3.0m |
Total Assets | 178.6m | 260.1m | 229.2m | 212.0m |
Accounts Payable | 2.9m | 3.3m | 4.6m | 3.9m |
Current Liabilities | 43.5m | 26.5m | 36.8m | 45.3m |
Total Liabilities | 104.8m | 100.7m | 101.0m | 97.1m |
Common Stock | 3.0k | 3.0k | 3.0k | |
Additional Paid-in Capital | 2.8m | 237.0m | 241.8m | 244.8m |
Retained Earnings | (68.8m) | (77.7m) | (114.3m) | (130.1m) |
Total Equity | (66.0m) | 159.3m | 128.1m | 114.9m |
Financial Leverage | -2.7 x | 1.6 x | 1.8 x | 1.8 x |
Morphic Therapeutic Cash Flow
Annual
| USD | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|
Net Income | (16.9m) | (23.8m) | (43.3m) |
Depreciation and Amortization | 434.0k | 539.0k | 821.0k |
Accounts Receivable | (3.5m) | ||
Accounts Payable | 285.0k | 862.0k | 3.2m |
Cash From Operating Activities | (15.4m) | 7.6m | (41.7m) |
Purchases of PP&E | (945.0k) | (659.0k) | (2.2m) |
Cash From Investing Activities | (907.0k) | (656.0k) | (136.0m) |
Long-term Borrowings | (333.0k) | (652.0k) | |
Cash From Financing Activities | 2.0m | 89.5m | 93.3m |
Net Change in Cash | 3.9m | 165.2m | (84.3m) |
Interest Paid | 31.0k | 68.0k | |
Income Taxes Paid | 550.0k |
Quarterly
| USD | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|
Net Income | (14.6m) | (23.5m) | (16.7m) | (32.6m) |
Depreciation and Amortization | 365.0k | 576.0k | 283.0k | 569.0k |
Accounts Receivable | (945.0k) | (2.4m) | (218.0k) | (64.0k) |
Accounts Payable | 1.2m | 1.5m | (307.0k) | (1.1m) |
Cash From Operating Activities | (13.9m) | (27.6m) | (18.9m) | (35.3m) |
Purchases of PP&E | (1.1m) | (1.4m) | (295.0k) | (385.0k) |
Cash From Investing Activities | (126.0m) | (91.8m) | 23.6m | 65.5m |
Cash From Financing Activities | (1.8m) | 93.3m | 803.0k | 1.3m |
Net Change in Cash | (141.7m) | (26.1m) | 5.5m | 31.6m |
Income Taxes Paid | 550.0k | 480.0k | 480.0k |
Morphic Therapeutic Ratios
| USD | FY, 2017 |
|---|---|
Financial Leverage | 1.2 x |
